<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03657966</url>
  </required_header>
  <id_info>
    <org_study_id>SOV06</org_study_id>
    <secondary_id>2017-002196-26</secondary_id>
    <nct_id>NCT03657966</nct_id>
  </id_info>
  <brief_title>DCVAC/OvCa After Standard-of-care Chemotherapy in Women With Relapse of Platinum-sensitive Epithelial Ovarian Cancer</brief_title>
  <official_title>An Open-label, Single-group, Multi-center, Phase II Clinical Trial Evaluating the Effect of Maintenance DCVAC/OvCa After Standard-of-care Therapy in Women With First Relapse of Platinum-sensitive Epithelial Ovarian Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sotio a.s.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Sotio a.s.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this trial is to investigate if maintenance DCVAC/OvCa after second-line
      chemotherapy of carboplatin/gemcitabine or carboplatin/paclitaxel improves efficacy outcomes
      in women with FIGO stage III and IV epithelial ovarian carcinoma who experienced relapse more
      than 6 months after complete remission of first line platinum-based chemotherapy (platinum
      sensitive ovarian cancer)
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      All patients who fulfill all eligibility criteria will undergo a leukapheresis procedure. All
      eligible/enrolled patients will receive standard-of-care therapy with carboplatin/gemcitabine
      or carboplatin/paclitaxel starting 2 to 7 days after leukapheresis.

      After 6 cycles of chemotherapy, patients will start maintenance treatment with DCVAC/OvCa.

      Treatment will continue irrespective of tumor progression until completion, refusal,
      intolerance of treatment or death.
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">November 23, 2017</start_date>
  <completion_date type="Anticipated">December 2023</completion_date>
  <primary_completion_date type="Anticipated">October 2020</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <intervention_model_description>open-label DCVAC/OvCa after treatment with carboplatin in combination with either gemcitabine or paclitaxel</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Progression Free Survival by modifications to the RECIST 1.1</measure>
    <time_frame>Assessed from enrollment up to 104 weeks</time_frame>
    <description>PFS as defined as the time from the first dose of Standard-of-Care (SoC) therapy administerd until tumor progression or death from any cause</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Overall survival</measure>
    <time_frame>Assessed from enrolment through study completion approximately 5 years</time_frame>
    <description>Defined as the time from first dose of SoC therapy administered until death due to any cause assessed until study completion</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Biological progression-free interval</measure>
    <time_frame>CA-125 assessed every 6 weeks up to 104 weeks</time_frame>
    <description>Defined by increasing CA-125 levels per Gynecologic Cancer Intergroup (GCIG) criteria</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Objective Response rate</measure>
    <time_frame>Response is assessed every 8 weeks up to 104 weeks</time_frame>
    <description>CR and PR measured by the modifed RECIST 1.1 criteria</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Immunologic Response</measure>
    <time_frame>Blood samples collected 5 times throughout the study from enrolment up to 104 weeks</time_frame>
    <description>Detection of entire anti-tumor immune response int he serum</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of Treatment-emergent adverse events [safety and tolerability]</measure>
    <time_frame>Screening through 30 days after completion of treatment</time_frame>
    <description>Safety profile as determined by the nature, incidence, duration, severity and outcome of adverse events (AEs) including serious AEs (SAEs) as assessed by CTCAE v. 4.0</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>CA-125 response</measure>
    <time_frame>CA-125 assessed every 6 weeks up to 104 weeks</time_frame>
    <description>Defined by GCIG criteria</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to either tumor or biologic Response</measure>
    <time_frame>From first dose of chemotherapy until either objective or serologic progression for up to 104 weeks.</time_frame>
    <description>Response according to RECIST or CA-125 measurements as increased to &gt;2 times ULN</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">33</enrollment>
  <condition>Ovarian Cancer Recurrent</condition>
  <arm_group>
    <arm_group_label>Standard of care chemotherapy + DCVAC/Ov</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Standard-of-care carboplatin/gemcitabine or carboplatin/paclitaxel followed by DCVAC/OvCa</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>DCVAC/OvCa</intervention_name>
    <description>activated dendritic cells (DCVAC/OvCa) for immune maintenance after chemotherapy</description>
    <arm_group_label>Standard of care chemotherapy + DCVAC/Ov</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Standard of Care Chemotherapy</intervention_name>
    <description>either carboplatin and gemcitabine or carboplatin and paclitaxel followed by DCVAC/OvCa</description>
    <arm_group_label>Standard of care chemotherapy + DCVAC/Ov</arm_group_label>
    <other_name>carboplatin with gemcitabine</other_name>
    <other_name>carboplatin with paclitaxel</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients with histologically confirmed FIGO stage III or IV epithelial ovarian,
             primary peritoneal or fallopian tube carcinoma (serous,endometrioid, or mucinous) who
             had complete remission after first-line platinum-based chemotherapy

          -  Radiologically confirmed relapse after &gt;6 months of remission ( platinum-sensitive
             cancer)

          -  Laboratory parameters per protocol

        Exclusion Criteria:

          -  FIGO I, II epithelial ovarian cancer

          -  FIGO III, IV clear cells epithelial ovarian cancer

          -  Non-epithelial ovarian cancer

          -  Borderline tumors ( tumors of low malignant potential)

          -  Prior or current systemic anti-cancer therapy for ovarian cancer (chemotherapy,
             monoclonal antibody therapy, tyrosine kinase inhibitory therapy, vascular endothelial
             growth factor or hormonal therapy) except first-line Pt based chemotherapy ( with or
             without bevacizumab)

          -  fertile women of child-bearing potential not willing to use a highly effective method
             of contraception or a combination of methods

          -  Pregnant of lactating women

          -  Pre-defined co-morbidities

          -  Known hypersensitivity to any constituent of DCVAC/OVCa or the selected chemotherapy
             compounds
      </textblock>
    </criteria>
    <gender>Female</gender>
    <gender_based>Yes</gender_based>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Harald Fricke, MD, PhD</last_name>
    <role>Study Director</role>
    <affiliation>Sotio a.s.</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University Hospital Brno</name>
      <address>
        <city>Brno</city>
        <zip>625 00</zip>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Masaryk Memorial Cancer Institute</name>
      <address>
        <city>Brno</city>
        <zip>656 53</zip>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Novy Jicin</name>
      <address>
        <city>Nový Jičín</city>
        <zip>741 01</zip>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Hospital in Ostrava</name>
      <address>
        <city>Ostrava</city>
        <zip>708 52</zip>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Hospital Plzen</name>
      <address>
        <city>Plzen</city>
        <zip>304 60</zip>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Hospital Kralovsko Vinohrady</name>
      <address>
        <city>Prague</city>
        <zip>100 34</zip>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>General University Hospital in Prague</name>
      <address>
        <city>Prague</city>
        <zip>128 08</zip>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Bulovka</name>
      <address>
        <city>Prague</city>
        <zip>180 81</zip>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Czechia</country>
  </location_countries>
  <verification_date>March 2020</verification_date>
  <study_first_submitted>August 24, 2018</study_first_submitted>
  <study_first_submitted_qc>August 30, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">September 5, 2018</study_first_posted>
  <last_update_submitted>March 18, 2020</last_update_submitted>
  <last_update_submitted_qc>March 18, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">March 19, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Immunotherapy</keyword>
  <keyword>Platinum-sensitive</keyword>
  <keyword>Biologic</keyword>
  <keyword>Vaccine</keyword>
  <keyword>Ovarian cancer</keyword>
  <keyword>Fallopian Tube cancer</keyword>
  <keyword>Primary peritoneal cancer</keyword>
  <keyword>dendritic cells</keyword>
  <keyword>chemotherapy</keyword>
  <keyword>leukapheresis</keyword>
  <keyword>FIGO III</keyword>
  <keyword>FIGO IV</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ovarian Neoplasms</mesh_term>
    <mesh_term>Carcinoma, Ovarian Epithelial</mesh_term>
    <mesh_term>Hypersensitivity</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Gemcitabine</mesh_term>
    <mesh_term>Paclitaxel</mesh_term>
    <mesh_term>Carboplatin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

